Systagenix has added another wound marker to its pipeline; Mitochondrial mutations lower in colon cancer cells;

> In an unexpected finding, mitochondrial mutations are lower in colon cancer cells than in healthy cells. Abstract

> Plasma tau levels could lead to a blood test to diagnose Alzheimer's disease. Press release

> U.K.-based wound diagnostic company Systagenix has acquired the assets of O2 Insights, adding a third marker to its wound diagnostics pipeline. Press release

> A p53 mutation can affect breast cancer response to doxorubicin. Press release

> N-terminal pro-brain natriuretic peptide (NT-proBNP) could be used to screen for systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). Abstract

> Interleukin-6 has potential as a biomarker for severe pandemic H1N1 influenza A infection. Paper

> In a German study, a genetic biomarker could tag lung cancer at an early stage. Press release

> A simple blood biomarker test, detecting levels of troponin T, could be used to detect an increased risk of death in the month after non-cardiac surgery. Press release

> Circulating tumor cells provide a blood "snapshot" for cancer drug response in neuroendocrine tumors. Press release | Abstract

> An immune system issue has been tied to a fourfold higher likelihood of death. Press release

And Finally… Biomarker-based diagnostics company Astute Medical has completed a $40.4 million Series C financing. Press release

Suggested Articles

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.